Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Looks To Model New Central Drug Authority After U.S. FDA

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - With elections to parliament slated for next year, India's Congress Party-led government is expected to soon pass a slew of bills in the pharmaceutical sector, including that for a central drug authority
Advertisement

Related Content

India’s Drug Watchdog DCGI Speeds Up Regulatory Overhaul; Single Window Clearance to Precede Central Drug Authority
India’s Drug Watchdog DCGI Speeds Up Regulatory Overhaul; Single Window Clearance to Precede Central Drug Authority
Parliamentary Panel Not Yet Ready To Recommend India’s CDA Bill
Parliamentary Panel Not Yet Ready To Recommend India’s CDA Bill
Lilly, Merck Deals Mark Start Of New Era For Indian Drug Firms – PharmAsia News Spotlight
Lilly, Merck Deals Mark Start Of New Era For Indian Drug Firms – PharmAsia News Spotlight
Booming Clinical Research Business Could Trigger Regulatory Overhaul In India
Booming Clinical Research Business Could Trigger Regulatory Overhaul In India
Advertisement
UsernamePublicRestriction

Register

SC067914

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel